Herantis Pharma Oyj (HRTIS) — Cash Flow-to-Debt Ratio
Herantis Pharma Oyj (HRTIS) has a Cash Flow-to-Debt Ratio of -1.01x as of June 2025, meaning its operating cash flow of €-3.39 Million could theoretically repay -1% of its total liabilities (€3.36 Million) in one year. See free cash flow generation of Herantis Pharma Oyj to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Herantis Pharma Oyj Cash Flow-to-Debt Ratio (2012–2024)
Historical debt coverage capacity for Herantis Pharma Oyj across 13 annual periods. Also explore HRTIS net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Herantis Pharma Oyj (2012–2024)
Year-by-year debt coverage analysis for Herantis Pharma Oyj. For market capitalisation and broader financial context, see how much is Herantis Pharma Oyj worth.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -2.33x | €-6.54 Million | €2.81 Million | ▼ -1.3% |
| 2023 | -2.30x | €-4.64 Million | €2.02 Million | ▼ -61.5% |
| 2022 | -1.42x | €-8.94 Million | €6.29 Million | ▲ +8.9% |
| 2021 | -1.56x | €-9.93 Million | €6.36 Million | ▼ -61.1% |
| 2020 | -0.97x | €-8.56 Million | €8.83 Million | ▼ -50.0% |
| 2019 | -0.65x | €-5.96 Million | €9.22 Million | ▼ -25.3% |
| 2018 | -0.52x | €-3.73 Million | €7.24 Million | ▼ -48.5% |
| 2017 | -0.35x | €-2.60 Million | €7.48 Million | ▲ +1.2% |
| 2016 | -0.35x | €-3.04 Million | €8.63 Million | ▲ +61.5% |
| 2015 | -0.91x | €-7.40 Million | €8.09 Million | ▼ -63.1% |
| 2014 | -0.56x | €-4.36 Million | €7.77 Million | ▼ -530.5% |
| 2013 | -0.09x | €-224.21K | €2.52 Million | ▲ +63.1% |
| 2012 | -0.24x | €-533.42K | €2.21 Million | — |